 |
|
|
Home > GERMANY > Molmed SpA
MOLMED SpA
Via Olgettina 58 – 20132 Milano, ITALY
Telephone: 0039 02 212771
Fax: 0039 02 21277220
Web site: www.molmed.com
E-mail: info@molmed.com
Contact: Mr. Holger Neecke (
Business Development Manager)
At a Glance
Status: SME
Founded: 1996
Employees: 71
Turnover: € 2.600.000.00
Main Activity
MolMed SpA is
a medical biotechnology company focused on Medical biotechnology with a primary focus on development of novel anticancer therapeutics, with three products in clinical development:
- TK: cell therapy enabling safe haploidentical haematopoietic stem cell transplantation (haplo-HSCT). Phase I/II completed in high-risk leukaemia, Phase III start in 2007
- ARENEGYR (NGR-hTNFa): vascular targeting agent for treatment of highly vascularised solid tumours. Phase II as single agent in colorectal cancer approved in October 2006. Phase I in combination with doxorubicin almost completed.
- M3TK: cancer therapeutic vaccine. Ongoing Phase I/II in adv. melanoma.
Company Strengths
HIGH QUALITY PRODUCTS: GMP production of clinical-grade materials for cell/gene therapy protocols. LICENSES/TRADE MARKS/QUALITY CERTIFICATIONS/PATENTS: Its patent portfolio includes assignee/applicant or licensee of 63 patent families, with 123 granted patents and 97 pending applications in EP, US and JP.
INNOVATIVE PROCESSES/SERVICES/PRODUCTS: MolMed has designed and developed novel vascular targeting agents; in the field of cell and gene therapy, MolMed has developed individual-specific cell modification for insertion of genes with therapeutic functions.
NETWORKING: MolMed has a master agreement with San Raffaele and a broad collaboration network with academic & clinical centres in Europe, US and Japan.
R&D CAPACITY: MolMed has a 1400 sqm dedicated facility and 52 full-time employees (82% of total work force).
EXPERTISE: MolMed is specialized in viral vectors, master cell banks, GMP production of cell/gene therapy products, regulatory support & QA.
Customer References
Industrial partner: Takara Bio Inc. (Japan) – licensee of 3 Molmed products for the Asian markets.
R&D partner: Telethon Foundation.
Sector
BIOTECHNOLOGY
MEDICAL BIOTECHNOLOGY
-Biopharmaceutical
-Drug development
-Immunology
-Process development
-Research and development
Type of Cooperation
GENERAL CO-OPERATION
-TECHNOLOGY TRANSFER OR PRODUCTION LICENSE
|
|
